In the past two decades, several clinical trials have been conducted to test combining RT with targeted therapies against radioresistance conferring proteins such as epidermal growth factor receptor (EGFR), histone deacetylase (HDAC) and the B-rapidly accelerated fibrosarcoma (BRAF), aiming to develop combined-modality treatment regimens with fewer side effects (5–7). Here, EGFR is linked to fibrosarcoma.